Report cover image

Growth Opportunities in Global Biotech Investment, 2024

Publisher Frost & Sullivan
Published Apr 09, 2024
SKU # MC18710485

Description

Growth Opportunities in Global Biotech Investment, 2024


Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Table of Contents

Transformation in Global Biotech Investment
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments
Ecosystem
Market Scope and Segmentation
Definitions
Growth Generator
Growth Drivers
Growth Restraints
The State of the Biotech Industry—Biologics Pipeline
State of the Biotech Industry—Biologics Industry Outlook
Biotech M&A Investment Outlook—2024
Biotech VC Investment Outlook—2024
Top 3 Predictions—2024
Top 3 Big Pharma Investment Strategies for Portfolio Remodeling
Emerging Biotech Companies Top Trends—Impact Summary
New Modalities Driving Precision Medicine Will Remain Attractive
Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology
Growth Generator: Biotech M&A
Biotech M&A Trends
Big Biopharma M&A Activity
Biotech M&A Analysis by Therapeutic Segment
Biotech M&A Analysis by Modality
Key Biopharma M&A Targets2024
Growth Generator: Biotech VC Investment
Biotech VC Financing Trend
Top VC Financing Deals
Biotech VC Deal Analysis by Funding Stage
Biotech VC Deal Analysis by Therapeutic Segment
Biotech VC Deal Analysis by Modality
Biotech VC Deal Analysis by Stage of Clinical Development
Companies to Action
Google Ventures (United States)
ARCH Ventures (United States)
RA Capital (United States)
SamsaraBio Capital (United States)
OrbiMed (United States)
Alexandria (United States)
Growth Opportunity Universe
Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies
Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies
Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies
Best Practices Recognition
Best Practices Recognition
Frost Radar
Frost Radar
Next Steps
Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
List of Exhibits
Legal Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us